---
title: "Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290458424.md"
description: "Aptevo Therapeutics disclosed that Niowave Inc. filed a Form 3 initial beneficial ownership statement on June 22, 2026. The filing indicates Niowave holds 98,522 shares of common stock directly as of May 25, 2026, and is identified as a 10% owner. Additionally, Niowave reported holding 53,201 warrants exercisable until May 25, 2031, with an exercise price of USD 8."
datetime: "2026-06-22T15:45:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290458424.md)
  - [en](https://longbridge.com/en/news/290458424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290458424.md)
generator: "portal-rs"
---

# Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc

-   Aptevo Therapeutics disclosed NioWave filed a Form 3 showing 98,522 shares of common stock held directly as of May 25, 2026. \* NioWave reported 53,201 warrants exercisable May 25, 2026, expiring May 25, 2031, with an exercise price of USD 8. \* The filing identified NioWave as a 10% owner. \* The Form 3 was signed June 22, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001666270-26-000003), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo Therapeutics announces special shareholder meeting](https://longbridge.com/en/news/297564634.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [Helen of Troy director Marlo Michelle Cormier Platz files initial beneficial ownership statement](https://longbridge.com/en/news/297833532.md)
- [Redcloud files Form 3 initial beneficial ownership statement for CFO David Sturgeon](https://longbridge.com/en/news/297696881.md)
- [Rubrik files Form 3 as director Rakefet Russak-Aminoach reports no holdings](https://longbridge.com/en/news/297373986.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**